Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

New Jersey Pharmaceutical Company Settles Pesticides Violations

By U.S. Environmental Protection Agency | November 2, 2017

(Credit: EPA via wikimedia commons)

EPA takes action to protect health care facilities from unregistered and mislabeled antimicrobial pesticides.

The U.S. Environmental Protection Agency (EPA) announced this week that it reached an agreement with Pharmaceutical Innovations of Newark, NJ resolving alleged violations of the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA). The EPA had alleged that Pharmaceutical Innovations sold and distributed the unregistered and misbranded antimicrobial pesticides “PI Spray” and “PI Spray 2.”

The unregistered and misbranded pesticides were used to clean ultrasound and mammography equipment and other surfaces in health care facilities. As a result of the settlement, Pharmaceutical Innovations stopped producing and selling their unregistered and misbranded products called “PI Spray” and “PI Spray 2” and did a voluntary recall of both products.

“These products were marketed to health care facilities and their patients, which of course relied on the claims that they kill microorganisms, but in this case those claims were not properly substantiated through the EPA registration process,” said Pete Lopez, EPA regional administrator. “When the EPA registers products, EPA requires that companies demonstrate that products do what they claim and that they don’t present unacceptable risk if used properly.”

The product labels, product inserts, and promotional material for both products:

  • made unsubstantiated claims to control bacteria and kill viruses; 
  • made unsubstantiated claims as to the efficacy and safety of the product; and 
  • did not list the inert ingredients or bear the name and percentage by weight of each active and inert ingredient. 

In the settlement, Pharmaceutical Innovations agreed to pay a civil penalty of $250,000 and certified that it has come into compliance with FIFRA. 

The sale and distribution of unregistered and misbranded antimicrobial pesticides pose a danger to people’s health. Without the company’s submission of efficacy and safety data and product labels to EPA for review and approval, as required by law, health care facilities and their patients may use the product inappropriately and are deprived of important health and safety information.   

The settlement will help ensure that sellers and distributors of antimicrobial products do not make claims about pesticides without first registering their products with EPA.  It will also help ensure that antimicrobial products are not mislabeled with unsubstantiated claims or without important information for use.

The goal of FIFRA is to promote the appropriate use of pesticides and to minimize the risks to the public, pesticide applicators, and the environment from their use. FIFRA requires that pesticides sold in the U.S. be registered with EPA to ensure they are effective for their intended use and distributed with labels bearing approved claims and all required information. Facilities that produce pesticides must also be registered with EPA and are required to submit annual production reports.

(Source: U.S. Environmental Protection Agency)

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE